US-Egypt Cooperative Research: Preparation of Haemophilus Influenza Type B/Tetanus Toxoid Conjugate Vaccine

美埃合作研究：B型流感嗜血杆菌/破伤风类毒素结合疫苗的制备

• 批准号: 9730757
• 负责人: Mary Mikhail
• 金额: $ 0.9万
• 依托单位: U.S. Naval Medical Research
• 依托单位国家: 美国
• 项目类别: Interagency Agreement
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-02-01 至 1999-01-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=9730757&HistoricalAwards=false
• 关键词: US; Egypt; Cooperative; Research; Preparation

Description: This award is for support of a cooperative project by Dr. Mary M. Mikhail, Senior Investigator, Enteric Microbiology, at the Naval Medical Research Unit -3 (NAMRU3) in Cairo, Egypt, and Alaa Eldin Shehata Aly, Senior Chemist, Biomedical Research Center, Egyptian Organization for Biological Products and Vaccines (VACSERA), in Cairo, Egypt. The two collaborators plan to synthesize a new vaccine for the protection of infants against Haemophilus influenza type b (Hib) diseases. The polysaccharide of Hib will be prepared and purified then depolymerized and uniterminally coupled to a carrier protein (150KD fraction of tetanus toxoid). This will improve its immunogenecity specially in infants and lead to a better protection and longer duration of immune response with T-cell dependent characters. The conjugate produced will be of high hapten load so will be more active in priming infants, and more active in adults. The improvement of the immune response of the conjugate will be tested in laboratory animals. Scope: This project will involve two laboratories with complementary capabilities to conduct research in an important industrial and health research field. Part of the research work will be conducted at VACSERA, including the purification of Hib CPS and the preparation of the conjugate. The steps of TT fractionation, Hib CPS depolymerization, periodate oxidation and chemical coupling will be jointly reviewed by VACSERA and the NAMRU3 teams. The chemical testing of the conjugate also will be carried out jointly. The animal immunization will be done at NAMRU3. Dr. Mikhail is an expert in biological chemistry and animal clinical testing. The Egyptian researcher is an expert in the field of polysaccharide protein conjugated vaccine preparation, and has experience in purification and testing of bacterial capsular polysaccharides. This proposal meets the INT objective of supporting US-foreign collaboration in areas of mutual benefit. The project was generated as a result of a workshop on biotechnology organized by the National Institutes of Health (NIH) and the Egyptian Government. NIH was involved in the evaluation of the project and in recommending its support. This project is being supported under the US-Egypt Joint Fund Program, administered by the US Department of State, which provides grants to scientists and engineers in both countries to carry out cooperative activities.

描述：该奖项是为了表彰埃及开罗海军第三医学研究单位(NAMRU3)的肠道微生物学高级研究员Mary M.Mikhail博士和埃及生物制品和疫苗组织(VACSERA)生物医学研究中心高级化学家Alaa Eldin Shehata Aly在埃及开罗的合作项目。这两位合作者计划合成一种新的疫苗，用于保护婴儿免受b型嗜血杆菌(Hib)疾病的侵袭。Hib的多糖将被制备和提纯，然后解聚，并以一种载体蛋白(破伤风类毒素的150KD部分)一步步偶联。这将提高其免疫原性，特别是在婴儿中，并导致更好的保护和更长的免疫反应持续时间，具有T细胞依赖的特征。产生的结合物将具有高的半抗原负载，因此在启动婴儿时会更活跃，在成年人中会更活跃。这种结合物对免疫反应的改善将在实验室动物身上进行测试。范围：该项目将涉及两个能力互补的实验室，在一个重要的工业和健康研究领域进行研究。部分研究工作将在VACSERA进行，包括Hib CPS的提纯和结合物的制备。VACSERA和NAMRU3团队将共同审查TT分馏、Hib CPS解聚、高碘酸盐氧化和化学偶联的步骤。共轭化合物的化学测试也将联合进行。动物免疫将在NAMRU3进行。米哈伊尔博士是生物化学和动物临床试验方面的专家。这位埃及研究人员是多糖蛋白结合疫苗制备领域的专家，在细菌荚膜多糖的纯化和检测方面有经验。这一建议符合支持美国与外国在互利领域进行合作的国际目标。该项目是由国家卫生研究院(NIH)和埃及政府组织的生物技术讲习班的结果。国家卫生研究院参与了对该项目的评估和对其支持的建议。该项目由美国国务院管理的美国-埃及联合基金项目提供支持，该项目为两国的科学家和工程师开展合作活动提供资助。